Context Therapeutics Inc.
CNTX
$0.8595
-$0.0134-1.54%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 7.66M | 7.44M | 7.22M | 7.06M | 6.88M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 38.30M | 31.63M | 29.92M | 32.55M | 20.03M |
Operating Income | -38.30M | -31.63M | -29.92M | -32.55M | -20.03M |
Income Before Tax | -34.21M | -27.63M | -26.73M | -30.15M | -18.57M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -34.21 | -27.63 | -26.73 | -30.15 | -18.57 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -34.21M | -27.63M | -26.73M | -30.15M | -18.57M |
EBIT | -38.30M | -31.63M | -29.92M | -32.55M | -20.03M |
EBITDA | -38.29M | -31.62M | -29.91M | -32.54M | -20.01M |
EPS Basic | -0.40 | -0.35 | -0.53 | -0.91 | -1.06 |
Normalized Basic EPS | -0.25 | -0.22 | -0.33 | -0.57 | -0.66 |
EPS Diluted | -0.44 | -0.39 | -0.57 | -0.91 | -1.06 |
Normalized Diluted EPS | -0.25 | -0.22 | -0.33 | -0.57 | -0.66 |
Average Basic Shares Outstanding | 352.79M | 312.56M | 233.34M | 167.37M | 102.86M |
Average Diluted Shares Outstanding | 352.79M | 312.56M | 233.34M | 167.37M | 102.86M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |